Erbasan Ozan, Kemaloğlu Cemal, Bayezid Omer
Department of Cardiovascular Surgery, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
Anadolu Kardiyol Derg. 2008 Nov;8 Suppl 2:131-47.
End-stage heart failure is still associated with a decrease in both quality and prognosis of life and one- year survival of these patients is below 50%. Heart transplantation remains the final therapeutic option for the treatment of irreversible end-stage heart failure in all age groups with adequate success rates. Survival of patients who underwent heart transplantation has improved incrementally in recent years, with 86% survival in the first year and over 50% survival at 10 years. Approximately 50% of patients live for more than 10 years after heart transplantation and 25% of patients live for more than 18 years. Improvement of the quality of life is an other benefit, while the patients were in NYHA class III-IV preoperatively, nearly all of them have an improved functional status with NYHA class I-II after transplantation. However, discrepancy between the number of candidates and number of available donors is still the major problem for the applicability of heart transplantation.
终末期心力衰竭仍然与生活质量下降和预后不良相关，这些患者的一年生存率低于50%。心脏移植仍然是所有年龄组不可逆终末期心力衰竭的最终治疗选择，成功率较高。近年来，接受心脏移植患者的生存率逐步提高，第一年生存率为86%，10年生存率超过50%。大约50%的患者在心脏移植后存活超过10年，25%的患者存活超过18年。生活质量的改善是另一个益处，术前患者处于纽约心脏协会（NYHA）III-IV级，几乎所有患者在移植后功能状态改善至NYHA I-II级。然而，候选者数量与可用供体数量之间的差异仍然是心脏移植应用的主要问题。
